Paradigm Biopharma
0 followers
‌
Paradigm Biopharma (PAR) listed on the ASX in August 2015. Paradigm Biopharma's focus is on repurposing pentosan polysulphate sodium (PPS) for the treatment of diseases sustained by inflammation, where a key feature of the activity of PPS is its anti-inflammatory and tissue regenerative properties.
Industries
Headquarters
Employees
Links
Org chart
Paul Rennie
Founder & Chairman
Paul Rennie
Collapse
Simon White
Director of Investor Relations
Michelle Coffey
Global Head of Regulatory Affairs
Donna Skerrett
Chief Medical Officer and Executive Director
Justin Cahill
Chief Financial Officer
Donna Skerrett M.D. Msc
Chief Medical Officer
Catherine Stapledon
R&d Translational Scientist
Jill Forrest
Clinical Operations Lead
